Register for our free email digests:
Division of AMAG Pharmaceuticals Inc.
Latest From GenPharm International Inc.
Admedus and its product mix was an unfolding success story – and still is, due to a restructuring of activities and a resetting of aims that have ensured the Australia-US tissue engineering company does not miss out on the opportunities it has crafted for itself. Chairman and interim CEO Wayne Paterson explains what changes were required and why.
There are not many companies whose R&D business model combines immunotherapies and a medtech cardio franchise, but for Australia’s Admedus it’s a plan that is working so far. And more original science could be added to the portfolio as the company moves increasingly away from its S&D roots.
- Generic Drugs
- Therapeutic Areas
- South America
- Parent & Subsidiaries
- AMAG Pharmaceuticals Inc.
- Senior Management
- David A Van Vliet, Pres. & CEO
- Contact Info
Phone: (314) 567-3307
10888 Metro Ct.
St. Louis, MO 63043-2413
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.